KENVUE INC
KVUENYSETrading Snapshot
- Day Range
- $17.68 – $18.10
- 52-Week Range
- $14.02 – $20.13
- Volume
- $4.34B
- Avg Volume
- $3.40B
- Shares Outstanding
- 1.92B
- Next Earnings
- Dec 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $15.12B
- Last Q Revenue
- $3.96B
- P/E Ratio
- 20.5
- P/S Ratio
- 2.2x
- EPS (TTM)
- $0.86
- Dividend Yield
- 5.86%
- Dilution (1yr)
- −0.5%
Why Investors Own KVUE
- ✓High-growth profile — revenue up +22.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
KENVUE INC
KVUE
StockOtter · stockotter.spaceAbout KENVUE INC
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%.
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
DALLAS, Sept. 28, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("Acquisition") of Kenv
Burning a Hole in My Pocket
I'm talking about the cash I have sitting here that I desperately want to get into the market. Earlier this year, I got a chunk of money from selling a house.
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.
5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.
The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20
Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can hold up long enough to matte